Coenzyme Q10 for Patients with Parkinson';s Disease: A Systematic Review and Meta-Analysis

Negida, Ahmed; Menshawy, Ahmed; Ashal, Gehad El; Elfouly, Yasmin; Hani, Yasmein; Hegazy, Yasmin; ghonimy, Samar El; Fouda, Samar; Rashad, Yomna

doi:10.2174/1871527314666150821103306

Cited by 60 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in humans have shown that CoQ 10 is safe and well-tolerated even at high doses (1200–2400 mg/day) although its effect on reversing functional decline of mitochondria is unclear (Schulz and Beal, 1995 ; McGarry et al, 2017 ). Two reviews on recent clinical trials testing CoQ 10 supplementation reported the lack of improvement in motor functions in patients with neurodegenerative diseases, which led the authors to conclude that the use of CoQ 10 in these patients is unnecessary (Liu and Wang, 2014 ; Negida et al, 2016 ). However, other clinical trials in patients suffering from Parkinson's, Huntington's, and Friedreich's ataxia suggest that CoQ 10 supplementation could delay functional decline, particularly with regard to Parkinson's disease (Beal, 2002 ; Shults, 2003 ).…”

Section: Coq 10 Supplementation In the Treatment Omentioning

confidence: 99%

Coenzyme Q10 Supplementation in Aging and Disease

et al. 2018

View full text Add to dashboard Cite

Coenzyme Q (CoQ) is an essential component of the mitochondrial electron transport chain and an antioxidant in plasma membranes and lipoproteins. It is endogenously produced in all cells by a highly regulated pathway that involves a mitochondrial multiprotein complex. Defects in either the structural and/or regulatory components of CoQ complex or in non-CoQ biosynthetic mitochondrial proteins can result in a decrease in CoQ concentration and/or an increase in oxidative stress. Besides CoQ10 deficiency syndrome and aging, there are chronic diseases in which lower levels of CoQ10 are detected in tissues and organs providing the hypothesis that CoQ10 supplementation could alleviate aging symptoms and/or retard the onset of these diseases. Here, we review the current knowledge of CoQ10 biosynthesis and primary CoQ10 deficiency syndrome, and have collected published results from clinical trials based on CoQ10 supplementation. There is evidence that supplementation positively affects mitochondrial deficiency syndrome and the symptoms of aging based mainly on improvements in bioenergetics. Cardiovascular disease and inflammation are alleviated by the antioxidant effect of CoQ10. There is a need for further studies and clinical trials involving a greater number of participants undergoing longer treatments in order to assess the benefits of CoQ10 treatment in metabolic syndrome and diabetes, neurodegenerative disorders, kidney diseases, and human fertility.

show abstract

Section: Coq 10 Supplementation In the Treatment Omentioning

confidence: 99%

Coenzyme Q10 Supplementation in Aging and Disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Many environmental risk factors affect the mitochondria (Abdulwahid Arif and Ahmad Khan, 2010). Unfortunately, the possibility of coenzyme Q supplementation (Beal, 1999;Ebadi et al, 2001) and the promising results of a phase II trial (Shults, 2005) did not translate into benefits for patients (Negida et al, 2016), thus suggesting that coenzyme Q is not the limiting factor able to rescue mitochondrial malfunctioning in neurons of the SN.…”

Section: Influence Of Pesticides and Related Environmental Toxics In mentioning

confidence: 99%

Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease

Franco

Rivas‐Santisteban

Reyes‐Resina

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

The exact cause of Parkinson's disease (PD), the second most prevalent neurodegenerative disease in modern societies, is still unknown. Many scientists point out that PD is caused by a complex interaction between different factors. Although the main risk factor is age, there are other influences, genetic and environmental, that individually or in combination may trigger neurodegenerative changes leading to PD. Nowadays, research remains focused on better understanding which environmental factors are related to the risk of developing PD and why. In line with the knowledge on evidence on exposures that prevent/delay PD onset or that impact on disease progression, the aims of this review were: (i) to comment on the non-genetic risk factors that mainly affect idiopathic PD; and (ii) to comment on seemingly reliable preventive interventions. We discuss both environmental factors that may affect the central nervous system (CNS) or the intestinal tract, and the likely mechanisms underlying noxious or protective actions. Knowledge on risk, protective factors, and mechanisms may help to envisage why nigral dopaminergic neurons are so vulnerable in PD and, eventually, to design new strategies for PD prevention and/or anti-PD therapy. This article reviews the variety of the known and suspected environmental factors, such as lifestyle, gut microbiota or pesticide exposition, and distinguishes between those that are harmful or beneficial for the PD acquisition or progression. In fact, the review covers one of the most novel players in the whole picture, and we address the role of microbiota on keeping a healthy CNS and/or on preventing the "side-effects" related to aging.

show abstract

“…To our knowledge there is only one meta‐analysis dealing with the potential of antioxidant supplements in Parkinson's disease (PD) management. The study found no benefits of the antioxidant (coenzyme Q10) for either slowing disease progression or symptoms relief (Negida et al., ).…”

Section: Health‐promoting Potential Of Stbsmentioning

confidence: 99%

Resveratrol and Related Stilbenoids, Nutraceutical/Dietary Complements with Health‐Promoting Actions: Industrial Production, Safety, and the Search for Mode of Action

Navarro

Pinilla

Ortiz

et al. 2018

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

This paper reviews the potential of stilbenoids as nutraceuticals. Stilbenoid compounds in wine are considered key factors in health-promoting benefits. Resveratrol and resveratrol-related compounds are found in a large diversity of vegetal products. The stilbene composition varies from wine to wine and from one season to another. Therefore, the article also reviews how food science and technology and wine industry may help in providing wines and/or food supplements with efficacious concentrations of stilbenes. The review also presents results from clinical trials and those derived from genomic/transcriptomic studies. The most studied stilbenoid, resveratrol, is a very safe compound. On the other hand, the potential benefits of stilbene intake are multiple and are apparently due to downregulation more than upregulation of gene expression. The field may take advantage from identifying the mechanism of action(s) and from providing useful data to show evidence for specific health benefits in a given tissue or for combating a given disease.

show abstract

Coenzyme Q10 for Patients with Parkinson';s Disease: A Systematic Review and Meta-Analysis

Cited by 60 publications

References 0 publications

Coenzyme Q10 Supplementation in Aging and Disease

Coenzyme Q10 Supplementation in Aging and Disease

Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease

Resveratrol and Related Stilbenoids, Nutraceutical/Dietary Complements with Health‐Promoting Actions: Industrial Production, Safety, and the Search for Mode of Action

Contact Info

Product

Resources

About